Optimise viewing for

Toggle between patient and health professional views. The patient version is simplified to help people easily find suitable trials, while the professional view provides full detail.

Health ProfessionalsPatients

RecruitingLast updated: 10 October 2025

APRISE: A study assessing how effective screening is in identifying early-stage pancreatic cancer among people with a high-riskAssess the effectiveness of the Australian Pancreatic High-RIsk ScrEening Program in identifying early-stage pancreatic cancer among high-risk individuals due to familial or genetic risk factors

Trial purpose

Medical clipboardDiagnostic

Tumor type

Upper gastrointestinal tract Cancers Upper gastrointestinal tract

Age

People18 - 90

Trial acronym

APRISE

Clinical summary

Summary

This study will assess the effectiveness of pancreatic screening in identifying early-stage pancreatic cancer among high-risk individuals. Significant emphasis is also placed on assessing the psychological perception of cancer surveillance and understanding its impact on high-risk population.

You may be eligible for this study if you have relatives with a history of pancreatic cancer, or high-risk pathogenic variants within the family.

Participants will undergo monitoring via endoscopic ultrasound or MRI to detect changes in the pancreas, for a period of 10 years.

Participants will be asked to complete an eligibility questionnaire, an enrolment questionnaire and then follow-up questionnaires annually which include updates to the participant's medical information, relevant risk factors associated with pancreatic cancer, and assessments to determine quality of life, as well as cancer risk perception and worry.

It is hoped that findings from this study will help improve the prognosis of pancreatic cancer by diagnosing precursor lesions or cancer in its early and asymptomatic stage, when surgery provides the best chance for a cure.

Conditions

This trial is treating people with a high-risk of pancreatic cancer, such as family history

Eligibility

Inclusion

Individuals aged 18 to 90 years old (inclusive) without history of PDAC meeting any of the following criteria:
a) 2 or more relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject and age 50+ years or 10 years younger than earliest PDAC in family at time of diagnosis.
b) 2 or more affected first degree relatives with PDAC and age 50+ or 10 years younger than earliest PDAC in family.
c) BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant and 1 first or second degree relative with PDAC and age 50+ or 10 years younger than earliest PDAC in family.
d) Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant and age 40+.
e) Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant and age 35+.
f) Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis and age 40+ or 20 years after onset of pancreatitis (whichever is earlier).

Exclusion

Participants will be excluded if they are considered clinically unfit to undergo surveillance by EUS or MRI.

Inclusion

  • You have the type of cancer, symptoms, or health risks that this clinical trial is focused on.

Exclusion

  • You have certain types of non-cancer medical conditions.
Message

Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

More information

Trial Identifiers

Information on this page is partially produced from ANZCTR *. View further details about this trial on the registry via the links below:

Trial sponsor

Epworth HealthCare, Pankind: Pancreatic Cancer Australia, The Victorian Government through the Victorian Cancer Agency

Scientific Title

Assess the effectiveness of the Australian Pancreatic High-RIsk ScrEening Program in identifying early-stage pancreatic cancer among high-risk individuals due to familial or genetic risk factors

Get Support

Peer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Peer Connect

Contact cancer support

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.

Get support

Multilingual information

Learn more about clinical trials through this collection of resources in languages other than English.

View information

CloseReport inaccuracy

Thank you for helping us to increase accuracy of the trial. Our team will validate the information and update the information as soon as possible.

HelpThis verification step helps prevent fraudulent transactions from automated software.
Submitting ... Please wait